Tg Therapeutics Inc.

6 trials 3 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

6 Countries active

8 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I

Phase III: 3 Phase II/III: 1 Phase II: 1 Phase I: 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Relapsing multiple sclerosis 6 Myasthenia gravis 1

Top IMPs

All trials

6 total

Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) Recruiting

2025-522257-19-00 Phase II/III 2 countries UBLITUXIMAB
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting

2025-523757-33-00 Phase II 1 country UBLITUXIMAB
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Phase III 1 country UBLITUXIMAB
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici… Ended

2025-521127-73-00 Phase III 4 countries UBLITUXIMAB
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Phase I 1 country UBLITUXIMAB
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Ended

2024-516680-91-00 Phase III 2 countries UBLITUXIMAB

Showing 1–6 of 6 trials

← All sponsors A–Z